Hepion pharmaceuticals, inc. (CTRV)
CashFlow / Quarterly
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13
Cash flows from operating activities:
Net loss

-1,894

-1,819

-1,020

-1,983

-2,572

-157

-4,029

-2,690

-5,774

2,049

-7,618

-4,505

-4,816

-5,206

-3,917

-3,030

-4,844

-5,375

-4,397

-3,104

-1,470

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-168

-182

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation

14

17

17

17

-198

62

152

217

391

273

554

427

501

428

227

234

10

929

677

399

112

-

-

-

-

Change in fair value of derivative instrument-warrants

5

-8

-199

-195

-941

-3,850

-135

-395

-93

-6,186

1,540

391

-60

-

-

-

-

0

0

0

387

-

-

-

-

Change in fair value of contingent consideration

-90

-120

-50

100

340

85

80

-240

29

-1,080

1,165

0

5

-

-

-

-

-

-

-

-

-

-

-

-

Change in the fair value of debt

3

22

94

59

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

-

-

25

23

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt discount recorded as interest expense

0

-0

417

69

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred taxes adjustment

-

-

-

-

0

0

0

-536

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on the sale of fixed assets

-

-

-

-

0

0

0

-4

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

-

-

25

23

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense on note payable to parent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

1

Depreciation and amortization expense

6

7

8

4

4

4

4

4

5

6

8

6

7

5

5

5

5

5

4

3

2

-

-

-

-

Changes in operating assets and liabilities:
Accounts payable and accrued expense

-850

1,018

-545

-46

-604

-948

509

146

14

471

-750

-1,937

88

784

527

-454

2,276

322

1,136

83

-25

-

-

-

-

Deferred rent liability

-

-

-

-

-0

-0

-0

-6

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable, accrued expenses and due to Synergy

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

69

Prepaid expenses and other assets

145

67

9

107

12

-27

-12

109

-53

-216

114

-278

92

-180

-15

-243

247

220

282

15

44

-

-

-

-

Net cash used in operating activities

-2,440

-1,802

-1,263

-2,058

-5,092

-3,543

-3,417

-3,592

-5,373

-4,248

-5,215

-

-4,377

-

-

-

-

-

-

-

-

-

-

-

-

Total Adjustments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,536

1,670

431

-5,073

8,974

-54

71

Net Cash used in Operating Activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,876

-5,484

-2,798

-4,339

-2,861

-1,433

-1,038

-692

-337

-222

-110

Cash flows from investing activities:
Proceeds from sale of fixed assets

-

-

-

-

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of property and equipment

6

0

7

37

-

-

-

-

-

-

-

-

-

0

0

0

6

0

29

10

43

-

-

-

-

Net cash provided by (used in) investing activities

-6

-0

-7

-37

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net Cash Used in Investing Activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-6

0

-29

-10

-43

-

-

-

-

Cash flows from financing activities:
Change in current portion of capital lease

-

-

-

-

-

-

-

-

-

0

0

0

10

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the issuance of common stock

-

-

-

-

0

0

0

1,635

1,169

12,851

711

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of short term debt and common stock

-

-

-

1,250

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the exercise of warrants

-

-

-

-

-

-

-

-

-

0

85

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from stock options exercised

-

-

-

-

-

-

-

-

-

0

4

24

2

0

0

0

33

-

-

-

-

-

-

-

-

Repayment of debt financing

0

0

946

303

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

1,505

-482

16,737

946

-1,107

9,995

2,000

1,635

1,169

11,096

801

-

2

-

-

-

-

-

-

-

-

-

-

-

-

Borrowings under demand note payable to Synergy

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

100

Net Cash provided by Financing Activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

13,525

33

-

-

-

-

0

2,859

150

100

Net decrease in cash

-

-

-

-1,149

-

-

-

-1,956

-4,204

6,845

-4,414

7,523

-4,375

1,447

-3,875

8,041

-2,772

-

-

-

-

-

-

-

-

Supplementary disclosure of cash flow information:
Cash paid for interest

0

17

0

8

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase in cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

109

8,056

-1,082

-692

2,506

-72

-10

Supplementary disclosure of non-cash financing activities:
Stock issued to employees in lieu of cash payment for accrued bonus

-

-

-

-

36

0

73

186

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock issued to employees in lieu of cash payment for accrued bonuses

-

-

-

-

-

-

-

-

148

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of convertible preferred stock

-

-

-

-

-

-

-

-

-

0

190

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of Series C, D and E Preferred stock discount upon conversion

-

-

4,642

24

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock for debt redemption

-0

-0

374

126

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Adoption of Lease accounting

130

-50

-40

733

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Series C
Conversion of convertible preferred stock

0

16

85

46

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-